about
Near IR heptamethine cyanine dye-mediated cancer imagingSelf-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.Shedding light on nanomedicine.Spatiotemporal controlled delivery of nanoparticles to injured vasculatureControlled synthesis of camptothecin-polylactide conjugates and nanoconjugatesPolylactide-cyclosporin A nanoparticles for targeted immunosuppression.A two-component pre-seeded dermal-epidermal scaffold.Aptamer photoregulation in vivoTranslocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions.The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cellsAnticancer Camptothecin-N-Poly(lactic acid) Nanoconjugates with Facile Hydrolysable Linker.New Strategies in Cancer Nanomedicine.Treatment of otitis media by transtympanic delivery of antibiotics.Synthesis and proton NMR spectroscopy of intra-vesicular gamma-aminobutyric acid (GABA).Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide).Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.Photoswitchable nanoparticles for in vivo cancer chemotherapyMicrodevices for nanomedicine.Smart chemistry in polymeric nanomedicine.Nanomedicines Targeting the Tumor Microenvironment.Controlled Photoredox Ring-Opening Polymerization of O-Carboxyanhydrides.Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.Redox-Responsive, Core Cross-Linked Polyester Micelles.Facile functionalization of polyesters through thiol-yne chemistry for the design of degradable, cell-penetrating and gene delivery dual-functional agents.Photoswitchable nanoparticles for triggered tissue penetration and drug delivery.Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications.Extended Release of Native Drug Conjugated in Polyketal Microparticles.Reversible cell-specific drug delivery with aptamer-functionalized liposomes.Biodegradable mesostructured polymer membranes.Drug-Initiated, Controlled Ring-Opening Polymerization for the Synthesis of Polymer-Drug Conjugates.The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules.Inorganic mercury detection and controlled release of chelating agents from ion-responsive liposomes.Controlled Ring-Opening Polymerization of O-Carboxyanhydrides Using a β-Diiminate Zinc Catalyst.Emerging strategies in near-infrared light triggered drug delivery using organic nanomaterials.Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles.Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles.Stereoselective photoredox ring-opening polymerization of O-carboxyanhydrides.Anticancer nanoparticulate polymer-drug conjugate.Lymphatic Biodistribution of Polylactide Nanoparticles
P50
Q24616262-B3A1C1C4-46FB-45B8-8A94-F3FF37015743Q30361067-00B9908B-152F-48E0-83BE-3E5BE280F298Q30447871-FAF601A1-623F-451D-AA35-3E3F574B2C3BQ33529582-0BC33DC3-02E2-41C8-98CC-1352BAB229F4Q33601744-55EB2F97-4100-456F-A01A-60E27160B90EQ34378940-8006E5F7-D4C2-4AEA-93BD-CEB81F66095EQ34622754-1C6589A9-64CA-4B98-A693-242198879A07Q34661329-94FA744F-ADDB-4485-89FA-BDD2950920E5Q35345277-FB7DF9C5-2BAD-4A45-A95D-666A22327F7FQ35567561-6546E35B-ED2A-45AD-BE97-00FBB7A895BFQ35628729-6583E010-FD57-4721-B52D-DA0B04C40F41Q35826459-926C0C4D-675F-4C45-BEC9-2AE92E0577E3Q36133289-59A80773-8CA9-42DD-BF70-AE2B3E0D861BQ36475840-BC1676BA-3CD9-4BE5-BF77-48A0CC34EE6BQ37056787-BEC0BDA5-3773-4FCA-A06B-2A82E33F239BQ37181752-168B256A-81AA-46E7-A9B5-EB3C352F967FQ37340860-F3072031-4FEB-4103-B700-EBF7E1B827C4Q38092178-32D9EB20-F5E1-413C-801E-FD6ADBA59A66Q38221776-A4221974-0D9C-4862-A705-688DFD1DC8A7Q38556806-B31AFA51-A278-4E2A-B383-B78BB1265665Q38843028-46C47E2E-98D3-4139-9580-E2A922F744FDQ38879435-6987A77E-1936-4510-8FD1-69E27F679FCFQ39249782-60B86834-2FF6-4EBC-8FD4-51B7586B7A78Q39249820-25395D49-0E61-4024-B6D8-97407AC52A18Q39386667-283DF3C7-BB2D-46BF-BB52-EE1E809EB25EQ39741335-EFFB21F2-9951-42C6-B2C6-42192C942DAEQ39791958-10396B68-D4DC-48B0-8C28-2ED67329ACD3Q39822336-322989A8-211B-4855-BA30-1249C96CEE66Q42688841-419B096D-7979-4F7E-840A-A4C04751C27EQ42978607-3A2E0683-C1F9-4668-ADE7-2ABB6CE7DDB0Q43078078-80ABF565-2181-45E3-B000-4F656333AAF8Q43271839-CF2E1B63-6DB5-429D-A530-DE4713989936Q45042538-18CFD7D1-A4C7-45D4-89E6-95958ED68018Q45060855-F801BB54-E5DA-45BE-8B95-0AD44C9080CEQ46091044-04D24491-8837-4D26-B530-87CCD80B5343Q46586587-E12279E4-4894-45F0-9B7B-B42CF8B201E1Q52314989-0FB9DD58-2E61-4EF4-8CE9-A5DDFD09B8B1Q55030497-14BA8173-A81A-4C43-98EB-377E2C959F4FQ57694457-7ED32361-34F0-4555-9783-AF20DACE0899
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rong Tong
@ast
Rong Tong
@en
Rong Tong
@es
Rong Tong
@nl
Rong Tong
@sl
type
label
Rong Tong
@ast
Rong Tong
@en
Rong Tong
@es
Rong Tong
@nl
Rong Tong
@sl
prefLabel
Rong Tong
@ast
Rong Tong
@en
Rong Tong
@es
Rong Tong
@nl
Rong Tong
@sl
P106
P108
P31
P496
0000-0002-2034-9272